Effect of somatostatin analogues on endocrine remission after stereotactic radiosurgery in soma-totropinomas
Stereotactic radiosurgery,secondary to pituitary adenoma resection,is able to achieve 60％-70％biochemical remission rates in patients with acromegaly.The treatment effect of radiosurgery is slow,requiring approximately 27.5-43.0 months from treatment to endocrine remission.Stereotactic radio-surgery,a commonly used type of radiation therapy in growth hormone-secreting pituitary adenomas,or som-atotropinomas,directs precise and high-dose ionizing radiation onto the tumors.Compared to traditional ra-diotherapy,stereotactic radiosurgery is able to achieve endocrine remission in a shorter time span.Clinical guidelines recommend that patients receiving radiation therapy often need to undergo pharmacological treat-ment with somatostatin analogues before radiotherapy,and use somatostatin analogues as transitional therapy after radiotherapy to further reduce the time to remission.Somatostatin analogues are the most commonly used type of drugs in acromegaly treatment.However,further exploration and research are needed to deter-mine whether the use of somatostatin analogues during the peri-radiosurgery period has an impact on the bio-chemical response of patients with acromegaly,and whether it is necessary to discontinue somatostatin ana-logues during this period of time.
万方数据
维普
